Skip to content

Het monitoren van bijwerkingen van geneesmiddelen op de poliklinieken van GGZ Drenthe/Monitoring of side effects of medication at outpatient departments of Mental Health Services Drenthe

‘Monitoring Outcomes of Psychiatric Pharmacotherapy in the Assen Region’ (MOPHAR) Phase 2 – a prospective observational cohort study

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
NL-OMON
Registry ID
NL-OMON22977
Enrollment
10000
Registered
2014-11-19
Start date
2015-01-01
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psychiatrische aandoeningen/psychiatric diseases, metabool syndroom/metabolic syndrome, angststoornissen/anxiety disorders, stemmingsstoornissen/mood disorders

Interventions

None listed

Sponsors

GGZ Drenthe Postbus 30007 9400 RA Assen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in MOPHAR research, a subject must meet all of the following criteria: • Visiting an outpatient department of MHS Drenthe (first time or follow-up visit); • Older than 18 years of age; • Signed informed consent;

Exclusion criteria

Exclusion criteria: In general, there are no exclusion criteria for inclusion in the MOPHAR cohort.

Design outcomes

Primary

MeasureTime frame
The efficacy, (cost)effectiveness and safety of psychiatric pharmacotherapy (after implementation of a monitoring programme): - monitoring outcomes, such as antropometric examinations, blood parameters, etc. - score on psychiatric questionnaires - patient characteristics such as pharmacogenetics or biomarker levels - medication usage Specific primary and secondary study parameters will be determined for each individual research question.

Secondary

MeasureTime frame
For example time (e.g. duration of psychotropic drug usage, duration of treatment at the outpatient department), costs, medication adherence, etc.

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)